| Bioactivity | COX-2-IN-21 (Compound 5c) is a selective and orally active COX-2 inhibitor with an IC50 of 0.039 μM. COX-2-IN-21 shows promising anti-inflammatory potential[1]. |
| Invitro | COX-2-IN-21 (Compound 5c) (50 mg/kg) shows better anti-inflammatory activity and is less ulcerogenic than Celecoxib[1].COX-2-IN-21 (50 mg/kg) displays potent inhibitory effect on the production of PGE2 greater than Celecoxib, decreases rat serum concentrations of both TNF-α (% inhibition = 55.349) and IL-6 (% inhibition = 61.561) in a comparable or better activity to Celecoxib[1]. |
| Name | COX-2-IN-21 |
| CAS | 2519631-11-7 |
| Formula | C21H22N6O4 |
| Molar Mass | 422.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Labib MB, et al. Novel tetrazole-based selective COX-2 inhibitors: Design, synthesis, anti-inflammatory activity, evaluation of PGE2, TNF-α, IL-6 and histopathological study. Bioorg Chem. 2020 Nov;104:104308. |
COX-2-IN-21
CAS: 2519631-11-7 F: C21H22N6O4 W: 422.44
COX-2-IN-21 (Compound 5c) is a selective and orally active COX-2 inhibitor with an IC50 of 0.039 μM. COX-2-IN-21 shows
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.